Speaker Highlight:
Prof. Jean-Jacques Fournié

- Research focuses on immuno-oncology, predicting therapeutic responses of γδ T-lymphocytes in cancer treatment with a focus on lymphomas.
- He is a founder of the innate immunity company “Innate Pharms, SAS”, founded in 1999 and became director of the Cancer Research Centre of Toulouse in 2010.
- He has published just under 200 papers with over 8000 citations between them in Journals such as Oncoimmunology, Frontiers in Immunology and the European Journal of Immunology.

Related Publications:
- Assessment of tumor-infiltrating TCRγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology.
- IL-33-expanded human Vy9Vδ2 T cells have anti-lymphoma effect in a mouse tumor model. Eur J Immunol.
- Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer. Oncoimmunology